This study was aimed to investigate the effectiveness of mindfulness-based cognitive therapy (MBCT) on depressive symptoms, brain potential, and neuroimmunoinflammatory factors in patients with depression. Sixty-four eligible patients according to the inclusion criteria were randomly divided into the control group and the observation group, with 32 patients in each group. The control group...
Serotonergic hallucinogens and cannabinoids may alter the recognition of emotions in facial expressions (REFE). Cannabidiol (CBD) attenuates the psychoactive effects of the cannabinoid-1 agonist tetrahydrocannabinol. Ayahuasca is a dimethyltryptamine-containing hallucinogenic decoction. It is unknown if CBD may moderate and attenuate the effects of ayahuasca on REFE. Seventeen healthy...
Psychedelic drugs have recently emerged as plausibly effective pharmacological agents for the management of depression, anxiety, and other neuropsychiatric conditions, including those that are treatment-resistent. The latter half of the 20th century marked a revolution in the treatment of mental illnesses, exemplified by the introduction of selective serotonin reuptake inhibitors and other...
N,N-dimethyltryptamine (DMT) is a naturally occurring serotonergic psychedelic found in natural plants around the globe. As the main psychoactive component in ayahuasca, which also contains monoamine oxidase inhibitors, DMT has been consumed as plant-based brew by indigenous peoples for centuries. Further research is required to delineate the therapeutic utility of DMT. Although previous...
The primary psychoactive drug in magic mushrooms, psilocybin, induces profound alterations in consciousness through the 5-HT2A receptor. This review consolidates current research findings to elucidate the pharmacology, safety profile, and clinical applications of psilocybin. Despite initial concerns that psilocybin could cause psychosis, contemporary research has demonstrated that psilocybin is...
Karis Will, Sergio Lázaro Martínez, Surya A Reis et al.
N,N-dimethyltryptamine (DMT) is a serotonergic psychedelic with a history of ethnobotanical use and emerging clinical efficacy for neuropsychiatric disorders. Following Julius Axelrod's pioneering studies showing DMT production in human tissues, DMT has been proposed as an endogenous neuromodulator because it is a serotonin 2A receptor (5-HT2A R) agonist. However, the DMT-producing enzyme,...
Background: Psilocybin is a serotonergic psychedelic that provides a pharmacological tool for examining neural activity associated with altered states of consciousness. Existing studies report reduced power (4-30 Hz) in posterior regions and altered functional connectivity (FC) at rest, but have typically involved small samples and coarse anatomical parcellations. Additionally, perceptual...
Abstract Background . It is widely accepted that beyond the pharmacological predictors, individuals’ pre-drug mental disposition, including intentions , influences the psychedelic experience. However, is it not fully clear how intentions and outcomes relate. This study explores the intention category and explicitness in association with outcomes. Methods . Content validated intention categories...
Abstract Ayahuasca, an amazonian brew containing the serotonergic psychedelic substance N,N-dimethyltryptamine (DMT), induces distinctive visual perceptual phenomenology, yet the neural mechanisms underlying the interplay between external visual drive and internal imagery remain unknown. Using a placebo-controlled, within-subject fMRI design, the present study investigated the impact of...
(±) 3,4-methylenedioxymethamphetamine (MDMA) is a recreationally abused psychostimulant that impairs memory performance. This effect is often attributed to a working memory impairment resulting from compromised serotonin systems. However, recent evidence from non-human animal experimental studies suggests that acute MDMA may indirectly impair memory performance through overstimulation of...